IMMX News and Press, Immix Biopharma Inc. From 09/19/23

2023-09-19 13:49:41 ET More on Immix Biopharma: Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech ...

Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. Plan for NXC-201 to expand into earlier lines of therapy, and beyond the 5% of U.S. hospitals that offer CAR-T today LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ...

2023-09-19 07:00:00 ET Summary In-licensing of NXC-201 transforms Immix into a mid-to-late stage BCMA-targeting CAR-T therapy with a differentiated tolerability profile. First and only CAR-T therapy in clinical development for AL amyloidosis. Recent months have seen the constr...

2023-09-07 10:38:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips A high-ranking official at the Federal Reserve has indicated that the US central bank is planning to maintain its benchmark interest rate during its September policy meeting. This decision co...

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announ...

2023-09-01 10:00:10 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents. Dr. Lentzsch is an internationally recognized expert in multiple myeloma...

2023-08-23 14:20:59 ET Immix Biopharma ( NASDAQ: IMMX ) said the FDA has granted orphan drug designation for its therapy candidate NXC-201 in the treatment of multiple myeloma. Shares of Immix were up 11% in afternoon trading following the news. Immix said that the designati...

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The $13.9 billion Multip...

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment appr...